Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short, not skinny: The distinct sarcopenia phenotype of pediatric primary sclerosing cholangitis-inflammatory bowel disease.

Journal of pediatric gastroenterology and nutrition·2026
Same author

Tasty&Healthy Exclusive Whole-Food Diet in Asymptomatic Children and Young Adults With Biologically Active Crohn's Disease: The TASTI-E Randomized Controlled Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Real-World Outcomes of Upadacitinib vs Risankizumab Among Anti-Tumor Necrosis Factor-Exposed Patients With Crohn's Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

An observational cohort study evaluating adalimumab concentrations for predicting non-recapture of biochemical response after dose escalation in patients with Crohn's disease experiencing secondary loss of response.

Journal of the Canadian Association of Gastroenterology·2026
Same author

β-Glucan and Inulin Estimated Intake Are Associated With Reduced Risk of Crohn's Disease, Improved Gut Barrier and Systemic Inflammation Markers, and Multi-Omic Signatures in a High-Risk Cohort.

Gastroenterology·2026
Same author

Interleukin23 Receptor Genetic Variants Associate With Crohn's Disease Risk and Microbiome Changes in Healthy First-Degree Relatives.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Related Experiment Video

Updated: Jun 21, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Budesonide for Crohn's disease.

Cynthia H Seow1, Eric I Benchimol, A Hillary Steinhart

  • 1Mount Sinai Hospital, C/O Room 445, 600 University Avenue, Toronto, Ontario, M5G 1X5, Canada.

Expert Opinion on Drug Metabolism & Toxicology
|July 21, 2009
PubMed
Summary

Budesonide effectively induces remission for mild to moderate Crohn's disease (CD) with fewer side effects than traditional corticosteroids. However, it is not effective for maintaining remission in CD patients.

Related Experiment Videos

Last Updated: Jun 21, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Crohn's disease involves recurrent gastrointestinal inflammation, often affecting the ileum and colon.
  • Conventional systemic corticosteroids are effective but carry significant risks of morbidity and mortality.
  • Budesonide offers targeted delivery and reduced systemic exposure, presenting a potentially safer alternative.

Purpose of the Study:

  • To evaluate budesonide's efficacy and safety in inducing and maintaining remission for Crohn's disease.
  • To compare budesonide with conventional corticosteroids in managing Crohn's disease.

Main Methods:

  • Review of clinical trials and pharmacological data on budesonide in Crohn's disease.
  • Analysis of budesonide's pharmacokinetic profile and its impact on systemic bioavailability.
  • Assessment of budesonide's efficacy in both induction and maintenance phases of Crohn's disease therapy.

Main Results:

  • Budesonide demonstrates proven efficacy in inducing remission for mild to moderate Crohn's disease.
  • Its localized action leads to limited systemic bioavailability and reduced adverse effects compared to systemic corticosteroids.
  • Budesonide was found to be ineffective in maintaining remission in patients with Crohn's disease.

Conclusions:

  • Budesonide is a safer option for inducing remission in mild to moderate Crohn's disease.
  • Its utility is limited to the induction phase, not for long-term maintenance of remission.
  • Further research may explore combination therapies for sustained Crohn's disease management.